China Surges Ahead in Biologics, Prompting Strategic Reset for Indian Pharma
Biologics complex therapies that include vaccines, monoclonal antibodies, and gene-based treatments are increasingly driving growth in the global pharma market. However, unlike traditional small-molecule drugs, they demand sophisticated manufacturing, advanced research capabilities, and deep investment in innovation ecosystems.
- By Newsdesk
- New Delhi
- Apr 01, 2026
China’s rapid ascent in the high-value biologics segment is reshaping the global pharmaceutical landscape, forcing Indian drugmakers to rethink long-term strategies and accelerate their transition beyond generics.
Biologics complex therapies that include vaccines, monoclonal antibodies, and gene-based treatments are increasingly driving growth in the global pharma market. However, unlike traditional small-molecule drugs, they demand sophisticated manufacturing, advanced research capabilities, and deep investment in innovation ecosystems.
China has moved decisively on all these fronts. Backed by significant state support, robust infrastructure, regulatory reforms, and aggressive talent development, the country has emerged as a formidable force in biotech innovation. Its companies are not only scaling up production but are also becoming preferred partners for global pharmaceutical giants seeking cutting-edge drug pipelines and cost efficiencies.
Recent trends underline this shift. Chinese firms have secured a dominant share of biotech contracts from international players, tightening their grip on global supply chains and innovation networks. This growing influence is turning China into a critical hub for early-stage drug development and licensing deals, with multinational companies increasingly sourcing novel therapies from the region.
For India, long known as the “pharmacy of the world” due to its strength in affordable generics, the challenge is becoming more acute. While Indian companies have made notable progress in biosimilars, the next phase of competition lies in original biologic innovation, a space where China is rapidly widening the lead.
Industry experts suggest that Indian drugmakers must now pivot decisively. This includes ramping up investments in research and development, building advanced biologics manufacturing capabilities, and forging global partnerships to access technology and markets. Strengthening the domestic innovation ecosystem and improving regulatory agility will also be critical to closing the gap.
The shift will not be easy. Biologics require long gestation periods, higher capital, and scientific risk-taking areas where India has historically lagged. Yet, the stakes are high. As global demand for complex therapies surges, the ability to compete in biologics will determine the future positioning of pharmaceutical powerhouses.
In this evolving race, India stands at a strategic crossroads: continue leveraging its generics dominance or make a bold leap into innovation-led biologics to stay relevant in the next era of global healthcare.
Source: The Times of India